Presbyopia

Bobby Saenz, OD, MS, FAAO, discusses his AOA 2022 presentation, "Extended Depth of Focus Lenses and Drops."

A pharmaceutical approach (pilocarpine hydrochloride ophthalmic solution 1.25% ) to improving near vision can be used with other technology, benefiting a wide variety of patients.

Companies are entering an exclusive licensing agreement for the development and commercialization of Brimochol PF and Carbachol PF in three new regions: Greater China, South Korea, and select Southeast Asian territories.

Advice for pilots to consider ahead of taking flight.

A look at the current and future landscape of treatment options for this age-related condition.

Trial data finds that CSF-1 (pilocarpine hydrochloride 0.4%), a preservative-free ophthalmic solution, met both its primary and secondary endpoints.

Study evaluated twice-daily administration of VUITY (pilocarpine HCI ophthalmic solution) 1.25% in adults with age-related blurry near Vision

There will be very little downside to optometrists and their practice in offering presbyopia-correcting drops to patients who want better vision without glasses or contact lenses.

Presbyopia awareness: Causes, risk factors, symptoms, correction options and market trends.

With advanced, easy-to-fit multifocal lens technologies, patients don’t need to compromise

The latest launches of BRIO-I and BRIO-II follow promising topline data from the phase 2 VIVD clinical study evaluating Brimochol PF.

CSF-1 is a preservative-free solution designed as an alternative to reading glasses for patients.

Pipeline treatments for presbyopia, myopia, and demodex are expanding rapidly

Latest innovations within the presbyopic landscape are proving game-changers for better patient treatment.

Physicians share tales of creative workarounds to cope with this condition.

An increase in popularity of the use of handheld electronics is resulting in changes in the postural and behavioral patterns of device users, as well as significant differences between presbyopes and non-presbyopes and between genders.

Researchers report “very good results" in assessing the visual results and patients satisfaction in a series of patients following following implantation of the AcrySof PanOptix trifocal IOL (Alcon).

Veteran optometrist has seen them all and is waiting for the next innovation

See our latest poll results

As the number of presbyopia patients continues to grow, so do their visual demands.

VUITY, developed by Allergan, is the first and only FDA-approved eye drop to treat presbyopia

This poll is for optometrists and eyecare professionals, only. It will close on Friday, November 5, 2021.

Innovative treatment options reflect a shift in focus

See our latest poll results

Orasis Pharmaceuticals drop in development for treating presbyopia